HOME
login
history
all enzymes
BRENDA home
History
Information on EC 1.1.1.B40 - 11beta-hydroxysteroid dehydrogenase (NAD+)
for references in articles please use BRENDA:EC1.1.1.B40preliminary BRENDA-supplied EC number
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.1.1.B40 11beta-hydroxysteroid dehydrogenase (NAD+)Specify your search results
Word Map
- 1.1.1.B40
- glucocorticoid
-
mineralocorticoid
- cortisone
- aldosterone
- hypertension
- 11-dehydrocorticosterone
- adrenal
- fetal
- urinary
- placenta
- carbenoxolone
- dexamethasone
- 11beta-hsds
-
beta-hsd1
-
glycyrrhetinic
- hypokalemia
- renin
- acth
- thf
- spironolactone
- hsd11b2
-
11-keto
- tetrahydrocortisol
-
liquorice
-
glycyrrhizic
-
cushing
-
adrenalectomized
-
beta-reductase
- drug development
-
3hcorticosterone
- pharmacology
-
oxoreductase
-
feto-placental
-
cortisol-cortisone
-
prereceptor
-
glucocorticoid-mediated
-
11-dehydro
- medicine
The enzyme appears in viruses and cellular organisms
Synonyms
11 beta-hydroxysteroid dehydrogenase, 11 beta-hydroxysteroid dehydrogenase type 2, 11beta-hydroxysteroid dehydrogenase 2, 11beta-hsd type 2, 11beta-ohsd, 11beta-hsd 2, 11-beta hydroxysteroid dehydrogenase type 2, 11-beta hydroxysteroid dehydrogenase type 1, type 2 11beta-hydroxysteroid dehydrogenase, 11beta hydroxysteroid dehydrogenase type 2, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
11beta-HSD
11beta-HSD1
11beta-HSD2
11beta-hydroxysteroid dehydrogenase 2
11beta-hydroxysteroid dehydrogenase type 1
11beta-hydroxysteroid dehydrogenase type 2
11betaHSD2
corticosteroid 11-beta-dehydrogenase isozyme 1
11beta-HSD2
-
-
11beta-hydroxysteroid dehydrogenase 2
-
-
11beta-hydroxysteroid dehydrogenase type 2
-
-
11beta-hydroxysteroid dehydrogenase type 2
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
-
-
-
-
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
substrate binding site structure, reaction mechanism involving Lys187 and Tyr183, active site structure involving a S-Y-K catalytic triad
-
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
the three-dimensional organization of the hydrophobic substrate binding pocket is responsible for species-specific variability of activity with different substrates, overview
-
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
the three-dimensional organization of the hydrophobic substrate binding pocket is responsible for species-specific variability of activity with different substrates, overview
-
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
the three-dimensional organization of the hydrophobic substrate binding pocket is responsible for species-specific variability of activity with different substrates, overview
-
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
the three-dimensional organization of the hydrophobic substrate binding pocket is responsible for species-specific variability of activity with different substrates, overview
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
the three-dimensional organization of the hydrophobic substrate binding pocket is responsible for species-specific variability of activity with different substrates, overview
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
the three-dimensional organization of the hydrophobic substrate binding pocket is responsible for species-specific variability of activity with different substrates, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
11beta-hydroxysteroid:NAD+ 11-oxidoreductase
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
1beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, no reductase activity in aldosterone-sensitive collecting duct
-
ir
2 7-oxocholesterol + 2 NADPH + 2 H+
7beta-hydroxycholesterol + 7alpha-hydroxycholesterol + 2 NADPH
isozyme 11beta-HSD1, stereospecific reaction
-
?
11-dehydrocorticosterone + beta-NADPH
corticosterone + beta-NADP+
low activity
-
r
11-dehydrocorticosterone + beta-NADPH
corticosterone + beta-NADP+
-
higher activity
-
r
11-dehydrocorticosterone + beta-NADPH
corticosterone + beta-NADP+
-
higher activity
-
r
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1, low activity
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
-
i.e. cortisol
i.e. cortisone
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
-
i.e. cortisol
i.e. cortisone
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, clear but not exclusive preference for NAD+, only oxidative activity
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, significant higher rate of conversion for 11-beta-HSD2 than for 11-beta-HSD1
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone
-
?
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, no enzyme activity in reverse reaction direction
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
?
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
Ovis aries aries
-
isoform 11beta-HSD2
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
Ovis aries aries
-
i.e. corticosterone
-
r
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
-
i.e. cortisone
i.e. cortisol
ir
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
-
important role in modulating mineralocorticoid and glucocorticoid receptor occupancy by glucocorticoids
i.e. cortisol
ir
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
-
isozyme 11beta-HSD1, stereospecific reaction, very low activity
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
isozyme 11beta-HSD1, stereospecific reaction, very low activity
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
isozyme 11beta-HSD1, stereospecific reaction
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
-
isozyme 11beta-HSD1, stereospecific reaction
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
-
isozyme 11beta-HSD1, stereospecific reaction
-
?
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
-
-
-
r
corticosterone + NAD+
11-dehydrocorticosterone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH
-
-
-
?
corticosterone + NAD+
11-dehydrocorticosterone + NADH
-
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH
-
isozyme 11beta-HSD2
-
?
cortisol + NAD+
cortisone + NADH
-
oxidase that inactivates glucocorticoids to their 11-oxo derivatives
-
?
cortisol + NAD+
cortisone + NADH
-
inactivation of the biologically active glucocorticoid
-
r
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the oxidative reaction with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2, inactivation of cortisol, which interacts with the mineralocorticoid receptor, isozyme 11beta-HSD2 inhibition leads to stimulation of sodium and water reabsorption and to an increase of the intravascular volume that suppresses renin and secondarily an increase of blood pressure
-
?
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction 11beta-HSD1 with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction of 11-beta-HSD1 with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 highly prefers the oxidation of cortisol
-
r
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 is involved in inactivation of glucocorticoids, forskolin is involved in regulation of isozyme 11beta-HSD2 via intracellular cAMP
-
ir
cortisol + NAD+
cortisone + NADH
-
levels of cortisol oxidation are comparable in the presence of either NADP+ or NAD+
-
?
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction of 11beta-HSD1 with cofactor NAD+
-
ir
cortisone + beta-NADPH
cortisol + beta-NADP+
-
higher activity
-
r
cortisone + NADPH
cortisol + NADP+
-
isozyme 11beta-HSD1, activation
-
?
cortisone + NADPH
cortisol + NADP+
-
isozyme 11beta-HSD1, low activity
-
r
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
?
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, high activity
-
r
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
?
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, preferred substrate, high activity
-
r
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
?
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, high activity
-
r
dexamethasone + NAD+
11-dehydromethasone + NADH
-
isoform 11beta-HSD2
-
ir
dexamethasone + NAD+
11-dehydromethasone + NADH
-
isoform 11-beta-HSD2 shows significantly higher rate of conversion than isoform 11-betaHSD1
-
ir
additional information
?
-
the enzyme plays a role in spermatogenesis
-
?
additional information
?
-
-
enzyme inhibition affects the glucocorticoid- and dexamethasone-mediated regulation of surfactant protein A metabolism, overview
-
?
additional information
?
-
-
proinflammatory cytokines inhibit placental isozyme 11beta-HSD2 activity through Ca2+ and cAMP pathways, overview
-
?
additional information
?
-
-
effects of hypertension on cardiac steroid metabolism, overview
-
?
additional information
?
-
-
estradiol has a regulatory function on the isozymes in the liver, isozyme 11beta-HSD1 expression is about 30% reduced in castrated male rats, while expression of isozyme 11beta-HSD2 is increased, overview
-
?
additional information
?
-
the enzyme plays a role in control of cortisol and spermatogenesis
-
?
additional information
?
-
-
physiological role of 11beta-hydroxysteroid dehydrogenase in limiting any local actions of glucocorticoids within the reproductive tissues
-
?
additional information
?
-
-
maximal rates for NADP+-dependent cortisol oxidation are 7.4-28.5fold greater than the Vmax for NADPH-dependent reduction of cortisone, and are comparable with the rates of NAD+-dependent cortisol metabolism
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
1beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, no reductase activity in aldosterone-sensitive collecting duct
-
-
ir
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
-
i.e. cortisol
i.e. cortisone
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
-
i.e. cortisol
i.e. cortisone
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone
-
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, clear but not exclusive preference for NAD+, only oxidative activity
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, significant higher rate of conversion for 11-beta-HSD2 than for 11-beta-HSD1
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone
-
-
?
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, no enzyme activity in reverse reaction direction
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
?
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
Ovis aries aries
-
isoform 11beta-HSD2
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
Ovis aries aries
-
i.e. corticosterone
-
r
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
-
i.e. cortisone
i.e. cortisol
ir
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
-
important role in modulating mineralocorticoid and glucocorticoid receptor occupancy by glucocorticoids
i.e. cortisol
ir
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
-
-
-
-
r
corticosterone + NAD+
11-dehydrocorticosterone + NADH
-
-
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH
-
isozyme 11beta-HSD2
-
-
?
cortisol + NAD+
cortisone + NADH
-
oxidase that inactivates glucocorticoids to their 11-oxo derivatives
-
-
?
cortisol + NAD+
cortisone + NADH
-
inactivation of the biologically active glucocorticoid
-
-
r
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the oxidative reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2, inactivation of cortisol, which interacts with the mineralocorticoid receptor, isozyme 11beta-HSD2 inhibition leads to stimulation of sodium and water reabsorption and to an increase of the intravascular volume that suppresses renin and secondarily an increase of blood pressure
-
-
?
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction 11beta-HSD1 with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction of 11-beta-HSD1 with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 highly prefers the oxidation of cortisol
-
-
r
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 is involved in inactivation of glucocorticoids, forskolin is involved in regulation of isozyme 11beta-HSD2 via intracellular cAMP
-
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction of 11beta-HSD1 with cofactor NAD+
-
-
ir
cortisone + NADPH
cortisol + NADP+
-
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
additional information
?
-
the enzyme plays a role in spermatogenesis
-
-
?
additional information
?
-
-
enzyme inhibition affects the glucocorticoid- and dexamethasone-mediated regulation of surfactant protein A metabolism, overview
-
-
?
additional information
?
-
-
proinflammatory cytokines inhibit placental isozyme 11beta-HSD2 activity through Ca2+ and cAMP pathways, overview
-
-
?
additional information
?
-
-
effects of hypertension on cardiac steroid metabolism, overview
-
-
?
additional information
?
-
-
estradiol has a regulatory function on the isozymes in the liver, isozyme 11beta-HSD1 expression is about 30% reduced in castrated male rats, while expression of isozyme 11beta-HSD2 is increased, overview
-
-
?
additional information
?
-
the enzyme plays a role in control of cortisol and spermatogenesis
-
-
?
additional information
?
-
-
physiological role of 11beta-hydroxysteroid dehydrogenase in limiting any local actions of glucocorticoids within the reproductive tissues
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
NAD+
-
-
285953, 667152, 667956, 668297, 669706, 670896, 688766, 693544, 697286, 699841, 699842, 700178, 711471, 711737, 712257, 713232
NAD+
-
levels of cortisol oxidation are comparable in the presence of either NADP+ or NAD+
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
-
-
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aR,6S,8aR)-6-hydroxy-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
-
-
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
-
-
(2E,4S)-4-hydroxy-5-[(1S,5S,6S)-6-(hydroxymethyl)-2-methylidenebicyclo[3.1.1]hept-6-yl]-2-methylpent-2-enoic acid
-
-
(3alpha,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
-
-
(3beta)-3-hydroxy-18,29-epoxyolean-12-ene-11,29-dione
IC50 value for isoform 11beta-HSD2 above 25 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-3-hydroxyandrost-5-en-17-one
-
treatment of rats induces a shift from isoform 11beta-HSD1 to 11beta-HSD2 expression, increasing conversion from active to inactive glucocorticoids. Dehydroepiandrosterone likely modulates the transcription of 11beta-HSD2 in a phosphatidylinositol-3 kinase/Akt-dependent manner by increasing CCAAT/enhancer-binding protein beta mRNA and protein expression
(3beta)-3-[(3-carboxypropanoyl)oxy]urs-12-en-28-oic acid
IC50 value for isoform 11beta-HSD2 above 3 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate
IC50 value for isoform 11beta-HSD1 above 1 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-(2-carboxy-ethylsulfonylamino)-11-oxoolean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-(2-methoxycarbonyl-ethylsulfonylamino)-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-acetoxy-N-methyl-N-hydroxy-11-oxoolean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetylamino-N-hydroxy-N-methyl-11-oxoolean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-amino-11-oxoolean-12-en-29-oic acid, diphenylmethyl ester
-
-
(3beta,18beta,20beta)-N-hydroxy-N-methyl-11-oxo-3-[(trifluoromethylsulfonyl)amino]-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-N-hydroxy-N-methyl-3-methoxyamino-11-oxo-olean-12-en-29-amide
-
-
(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-[(methylsulfonyl)amino]-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl acetate
IC50 value for isoform 11beta-HSD1 above 40 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
11-oxo-allopregnanolone
-
inhibition of both isozymes 11beta-HSD1 and of isozyme 11beta-HSD2
11beta,21-dihydroxypregn-4-en-3,20-dione
-
11-beta-HSD2, 50% inhibition at 0.00001 mM
11beta-hydroxytestosterone
-
inhibition of both isozymes 11beta-HSD1 and of isozyme 11beta-HSD2
17beta-estradiol
-
decrease in isoform HSD2 protein in male, but not female, fetal lung explant
18beta-glycyrrhetinic acid
-
inhibits both 11beta-HSD1 and 11beta-HSD2, but preferentially inhibits 11beta-HSD2
3-(3,4,7-trimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3,4-dimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-bromotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-fluorotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-phenyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
-
IC50 in the presence of NADP+: 0.12 mM, IC50 in the presence of NAD+: 5.6 mM; i.e. CHAPS
3alpha,5alpha-tetrahydrocorticosterone
-
inhibition of isozyme 11beta-HSD1 and isozyme isozyme 11beta-HSD2
4-nonylphenol
-
inhibition of liver isozyme 11beta-HSD1 and kidney isozyme 11beta-HSD2, 11beta-HSD1 IC50: 49.3 mM, isozyme 11beta-HSD2 IC50: 0.0203 mM
BVT-14225
-
isozyme 11beta-HSD1 IC50: 52 nM, 1000fold less potent against isozyme 11beta-HSD2
Cd2+
the ERK1/2 inhibitor U0126 can block cadmium-induced inhibition of placental 11beta-HSD2. Cadmium does not alter activities of p38 MAPK, JNK, or PI3 kinase. Cadmium specifically activates the ERK1/2 signaling pathway in human trophoblast cells
curcumin
inhibitory against isoform 11beta-HSD2 in intact cells with IC50 value of 14.56 microM
estradiol
-
50% inhibition, DTT protects at 10 mM, estradiol has a regulatory function on the isozymes in the liver
interleukin-1beta
-
inhibits isozyme 11beta-HSD2, forskolin acts antagonistically strongly
-
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
mono-(2-ethylhexyl) phthalate
-
mono-(2-ethylhexyl) phthalate inhibits mRNA level and enzyme activity of 11beta-HSD2 in LbetaT2 cells at 0.0001 mM
sterenin A
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin B
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin C
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin D
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
-
-
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
-
-
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
-
-
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
-
-
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
-
-
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
-
-
3-((3r,5r,7r)-adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 74 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-((3r,5r,7r)-adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 74 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3,4,7-trimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 180 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3,4,7-trimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 180 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3,4-dimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 13 nM, isozyme 11beta-HSD2 IC50: 0.00255 mM
3-(3,4-dimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 13 nM, isozyme 11beta-HSD2 IC50: 0.00255 mM
3-(3,5-dimethyladamantylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 36 nM, isozyme 11beta-HSD2 IC50: 0.0176 mM
3-(3,5-dimethyladamantylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 36 nM, isozyme 11beta-HSD2 IC50: 0.0176 mM
3-(3-bromotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 23 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3-bromotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 23 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3-fluorotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 37 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3-fluorotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 37 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3-phenyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 2.3 nM, isozyme 11beta-HSD2 IC50: 23 nM
3-(3-phenyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 2.3 nM, isozyme 11beta-HSD2 IC50: 23 nM
3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)tricyclo[3.3.1.13,7]decan-1-ol
isozyme 11beta-HSD1 IC50: 739 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)tricyclo[3.3.1.13,7]decan-1-ol
isozyme 11beta-HSD1 IC50: 739 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(adamantan-1-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
isozyme 11beta-HSD1 IC50: 7.8 nM, isozyme 11beta-HSD2 IC50: above 0.003 mM
3-(adamantan-1-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
isozyme 11beta-HSD1 IC50: 98 nM, isozyme 11beta-HSD2 IC50: above 0.01 mM
3-(tricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 7.7 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(tricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 7.7 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
-
IC50: 0.254 mM; i.e. glycyrrhetinic acid
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
-
IC50 in the presence of NAD+: 0.000097 mM, IC50 in the presence of NADP+: 0.0003 mM; i.e. glycyrrhetinic acid
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
-
i.e. glycyrrhetinic acid; potent inhibition
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
-
i.e. glycyrrhetinic acid; more effective for 11-dehydrogenase than for 11-oxoreductase activity
adamantyl triazoles
eight derivatives of different ring size, IC50 of 1.4-2180 nM for isozyme 11beta-HSD1, and of 8.7-2000 nM for isozyme 11beta-HSD2, the IC50 value decreases with increasing ring size, overview
-
adamantyl triazoles
eight derivatives of different ring size, IC50 of 1.4-2180 nM for isozyme 11beta-HSD1, and of 8.7-2000 nM for isozyme 11beta-HSD2, the IC50 value decreases with increasing ring size, overview
-
dicyclohexyl phthalate
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0465 mM
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
-
-
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
-
-
mono (2-ethylhexyl) phthalate
-
competitive inhibitor of 11beta-HSD2, possibly via competing with the cofactor NAD+
mono (2-ethylhexyl) phthalate
-
competitive inhibitor of 11beta-HSD2, possibly via competing with the cofactor NAD+
n-alkyl-substituted adamantyl triazoles
substituted with methyl to butyl groups, IC50: of 3-72 nM for isozyme 11beta-HSD1, and of about 0.004 mM for isozyme 11beta-HSD2, overview
-
n-alkyl-substituted adamantyl triazoles
substituted with methyl to butyl groups, IC50: of 3-72 nM for isozyme 11beta-HSD1, and of about 0.004 mM for isozyme 11beta-HSD2, overview
-
additional information
-
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
inhibitory effects, antogonistic and agonistic effects of inhibitors and compounds, overview, no inhibition of isozyme 11beta-HSD2 by 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate
-
additional information
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
no effect on isoform HSD2 protein level: 5alpha-dihydrotestosterone
-
additional information
-
not inhibited by dimethyl phthalate, butylbenzyl phthalate, di(2-ethylhexyl) phthalate, di-n-heptyl phthalate, diisononyl phthalate, and diisodecyl phthalate
-
additional information
-
18alpha-glycyrrhetinic acid, selective inhibition of 11beta-HSD1, does not inhibit 11beta-HSD2 at concentrations up to 0.02 mM
-
additional information
the JNK inhibitor SP600125 has no effect on 11beta-HSD2 enzyme activity
-
additional information
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
steroid hormones, adrenocorticosteroid derivatives, progesteron and androgen steroid hormones, with 5alpha-ring A reduced-configuration selectively inhibit isozyme 11beta-HSD2, while 5beta-derivatives are inactive
-
additional information
-
isozyme 11beta-HSD1 expression is about 30% reduced in castrated male rats, while expression of isozyme 11beta-HSD2 is increased, overview
-
additional information
-
isozyme 11beta-HSD2 expression is highly reduced in proliferating cells
-
additional information
-
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
not inhibited by dimethyl phthalate, butylbenzyl phthalate, di(2-ethylhexyl) phthalate, di-n-heptyl phthalate, diisononyl phthalate, and diisodecyl phthalate
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
17alpha,20beta-dihydroxy-4-pregnen-3-one
activates in immature testis
dexamethasone
-
after application of dexamethasone, 11beta-HSD1 mRNA increases in muscle of both diabetic and control subjects, whereas 11beta-HSD2 mRNA decreases. 11beta-HSD1 activity increases in diabetic subjects, but not in controls, whereas 11beta-HSD2 activity does not change in either group
prostaglandin E2
-
stimulation of progesterone production and of 11beta-hydroxysteroid dehydrogenase activity via the prostaglandin E receptor 2-cAMP signalling pathway in luteinizing granulosa cells
additional information
-
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
additional information
the JNK inhibitor SP600125 has no effect on 11beta-HSD2 enzyme activity
-
additional information
-
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00089
17,21-dihydroxy-pregn-4-ene-3,11,20-trione
-
i.e. cortisone, temperature not specified in the publication, pH 5.5-6
0.0022
21-hydroxy-pregn-4-en-3,11,20-trione
-
temperature not specified in the publication, pH 5.5-6
0.00038
11-Dehydrocorticosterone
-
pH 7.4, 37°C, recombinant isozyme 11beta-HSD1
0.00042
11-Dehydrocorticosterone
pH 7.4, 37°C, recombinant isozyme 11beta-HSD1
0.00043
11-Dehydrocorticosterone
pH 7.4, 37°C, recombinant isozyme 11beta-HSD1
0.00045
11-Dehydrocorticosterone
pH 7.4, 37°C, recombinant isozyme 11beta-HSD1
0.00057
11-Dehydrocorticosterone
-
pH 7.4, 37°C, recombinant isozyme 11beta-HSD1
0.00085
11-Dehydrocorticosterone
-
pH 7.4, 37°C, recombinant isozyme 11beta-HSD1
0.0014
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione
-
i.e. cortisol, temperature not specified in the publication, pH 5.5-6
0.000084
11beta,21-dihydroxypregn-4-en-3,20-dione
-
temperature not specified in the publication, pH 5.5-6
0.00108
11beta,21-dihydroxypregn-4-en-3,20-dione
-
temperature not specified in the publication, pH 9
0.000154
cortisol
-
enzyme from testis, cosubstrate NAD+, 37°C, pH not specified in the publication
0.000208
cortisol
-
enzyme from bulbourethral gland, cosubstrate NAD+, 37°C, pH not specified in the publication
0.000226
cortisol
-
enzyme from caput epididymidis, cosubstrate NAD+, 37°C, pH not specified in the publication
0.0000044
NAD+
-
reduction of corticosterone, pH and temperature not specified in the publication
0.0000102
NAD+
-
kidney homogenate, pH and temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.002
2'-hydroxyflavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0049
2'-hydroxyflavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.0049
2'-hydroxyflavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0097
2'-hydroxyflavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.017
2'-hydroxyflavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.019
2'-hydroxyflavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.05
2'-hydroxyflavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.2
2'-hydroxyflavanone
above, pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.0021
abietic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0039
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.0052
abietic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0061
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0064
abietic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.007
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.007
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.011
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.00011
carbenoxolone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00023
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.00023
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00028
carbenoxolone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00034
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.00035
carbenoxolone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00059
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.00094
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00055
chenodeoxycholic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00077
chenodeoxycholic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0021
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.0021
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0025
chenodeoxycholic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.003
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.02
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.035
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0012
flavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.015
flavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.031
flavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.031
flavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.034
flavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.035
flavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.054
flavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.2
flavanone
above, pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.000028
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.00012
glycyrrhetinic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00012
glycyrrhetinic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00025
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00029
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.0003
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.00033
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00044
glycyrrhetinic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.000006
T0504
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.000015
T0504
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.000025
T0504
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.000025
T0504
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00008
T0504
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.000082
T0504
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00043
T0504
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0018
T0504
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0000049
(3alpha,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.00075
(3beta)-3-(acetyloxy)-11-oxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000029
(3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate
Homo sapiens
pH 7.4, 37°C
0.000122
(3beta)-N,3-dihydroxy-11-oxoolean-12-en-30-amide
Homo sapiens
-
pH not specified in the publication, 37°C
0.000458
(3beta,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000611
(3beta,18beta,20beta)-3-acetoxy-N-hydroxy-11-oxo-olean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000029
(3beta,18beta,20beta)-3-acetoxy-N-methyl-N-hydroxy-11-oxoolean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37°C
0.00213
(3beta,18beta,20beta)-3-hydroxy-N-methoxy-11-oxo-olean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000145
(3beta,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.000268
(3E)-3-(methoxyimino)-11-oxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000069
(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-[(methylsulfonyl)amino]-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl acetate
Homo sapiens
pH 7.4, 37°C
0.000061
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione
Homo sapiens
-
i.e. cortisol, pH and temperature not specified in the publication
0.0000051
11beta,21-dihydroxypregn-4-en-3,20-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000329
3,11-dioxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
5.6
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
Homo sapiens
-
pH and temperature not specified in the publication
0.008
5alpha-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one
Ovis aries aries
-
IC50: 0.008 mM
0.00000071
glycyrrhizinic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000071
glycyrrhizininc acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
additional information
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
0.00088
(+/-)-gossypol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.000097
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
carbenoxolone
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0465
dicyclohexyl phthalate
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37°C
0.0000024
glycyrrhetinic acid
Homo sapiens
-
cell-based assay, pH not specified in the publication, temperature not specified in the publication
0.0168
mono-(2-ethylhexyl) phthalate
Mus musculus
-
11beta-HSD2 from LbetaT2 cell microsomes, in PBS (pH 7.4), at 37°C
0.3279
mono-(2-ethylhexyl) phthalate
Mus musculus
-
11beta-HSD2 from kidney microsomes, in PBS (pH 7.4), at 37°C
additional information
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
Homo sapiens
-
IC50 = 0.0254 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aR,6S,8aR)-6-hydroxy-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
Homo sapiens
-
IC50 above 0.1 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
Homo sapiens
-
IC50 = 0.0015 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(2E,4S)-4-hydroxy-5-[(1S,5S,6S)-6-(hydroxymethyl)-2-methylidenebicyclo[3.1.1]hept-6-yl]-2-methylpent-2-enoic acid
Homo sapiens
-
IC50 = 0.0106 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(2S)-5-(acetyloxy)-2-hydroxypentyl acetate
Homo sapiens
-
IC50 = 0.177 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(3alpha,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
Homo sapiens
-
50% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3alpha,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oicacid
Homo sapiens
-
4% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3alpha,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
4% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta)-3-hydroxy-11-oxoolean-12-en-30-amide
Homo sapiens
-
13% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-11-oxo-3-succinylamino-olean-12-en-29-oic acid
Homo sapiens
-
13% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
Homo sapiens
-
22% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3,N-dihydroxy-N-methyl-11-oxo-olean-12-en-29-amide
Homo sapiens
-
7% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-(2-carboxy-ethylsulfonylamino)-11-oxoolean-12-en-29-oic acid
Homo sapiens
-
40% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-(2-methoxycarbonyl-ethylsulfonylamino)-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
3% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-acetoxy-N-methoxy-11-oxo-olean-12-en-29-amide
Homo sapiens
-
36% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-acetylamino-N-hydroxy-N-methyl-11-oxoolean-12-en-29-amide
Homo sapiens
-
4% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-amino-11-oxoolean-12-en-29-oic acid, diphenylmethyl ester
Homo sapiens
-
42% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
4% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-N-hydroxy-N-methyl-11-oxo-3-[(trifluoromethylsulfonyl)amino]-olean-12-en-29-amide
Homo sapiens
-
44% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-N-hydroxy-N-methyl-3-methoxyamino-11-oxo-olean-12-en-29-amide
Homo sapiens
-
30% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
Homo sapiens
-
IC50 = 0.177 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
Mus musculus
-
IC50 = 0.2505 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
Homo sapiens
-
IC50 = 0.22 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
Mus musculus
-
IC50 = 0.3303 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
Homo sapiens
-
IC50 = 0.2 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
Mus musculus
-
IC50 = 0.5002 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
2-oxopentane-1,5-diyl diacetate
Homo sapiens
-
IC50 = 0.0051 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
2-oxopentane-1,5-diyl diacetate
Mus musculus
-
IC50 = 0.0323 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
5-hydroxy-4-oxopentyl acetate
Homo sapiens
-
IC50 = 0.0389 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
5-hydroxy-4-oxopentyl acetate
Mus musculus
-
IC50 = 0.1291 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
BVT-14225
Homo sapiens
-
isozyme 11beta-HSD1 IC50: 52 nM, 1000fold less potent against isozyme 11beta-HSD2
additional information
carbenoxolone
Homo sapiens
-
2% residual activity at 0,001 mM, pH not specified in the publication, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
splanchnic, visceral, and hepatic net cortisol balance, cortisol uptake, and cortisol production, overview
additional information
-
determination of activity of isozyme 11beta-HSD2 in ovarian cancer, overview
additional information
-
isozyme expression, and isozyme and cofactor specific activities in kidney microsomes, overview
additional information
-
isozyme 11beta-HSD2 activity and plasma corticosterone are determined in toads from pre- (PR), post- (P), and reproductive (R) periods, activity is highest in P period, overview
additional information
-
the intrinsic activities of squirrel monkey and human enzyme are similar
additional information
isozyme activity in testicular tissue and glucocorticoid concentration, overview; isozyme activity in testicular tissue and glucocorticoid concentration, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
6.5
7.4
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
gene 11beta-HSDsf, enzyme short form; Japanese eel, gene 11beta-HSDsf
SwissProt
brenda
isozyme 11beta-HSD1; gene HSD11B1, isozyme 11beta-HSD1
SwissProt
brenda
-
285951, 285953, 285955, 655162, 668432, 687328, 687961, 688766, 693380, 693544, 695443, 697286, 697720, 699841, 699842, 700178, 701239, 711471, 711694, 711737, 712257, 713232
-
-
brenda
seven different women with ovarian cancer of different types, overview
-
-
brenda
-
285950, 285956, 285958, 654171, 654196, 655349, 656350, 656372, 667148, 687317, 697286, 699841, 701239, 725818, 743434
-
-
brenda
Wistar-Kyoto rats and Dahl salt-sensitive and salt-resistant rats, isozymes 11beta-HSD1 and 11beta-HSD2
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
presence of 11beta-hydroxysteroid dehydrogenase mRNA transcripts and protein in all tissues of the reproductive tract examined, but cortison-cortisol interconversion is undetectable in the corpus and cauda epididymides, vas deferens, vesicular and prostate glands
brenda
-
presence of 11beta-hydroxysteroid dehydrogenase mRNA transcripts and protein in all tissues of the reproductive tract examined, but cortison-cortisol interconversion is undetectable in the corpus and cauda epididymides, vas deferens, vesicular and prostate glands
brenda
-
expression of mRNA for 11beta-hydroxysteroid dehydrogenase type 1, 11beta-hydroxysteroid dehydrogenase type 2 and for glucocorticoid receptor during the estrous cycle. Level of 11beta-hydroxysteroid dehydrogenase type 1 mRNA is higher at the regressed state than at the other stages, whereas level of 11beta-hydroxysteroid dehydrogenase type 2 mRNA is lower at the regressed stage than at the other stages
brenda
-
of normotensive and hypertensive rats, the latter are hyperthrophied and fibrotic and have structural alterations in the coronary circulation, expression of isozymes 11beta-HSD1 and 11beta-HSD2, overview
brenda
-
11beta-HSD2, but not 11beta-HSD1, is strongly expressed in LbetaT2 cells
brenda
-
of neonatal pig. High expression of 11beta-hydroxysteroid dehydrogenase type 2 mRNA, resulting in oxidation from cortisol to cortison, with no detection of the reduction reaction. Activity of type 2 enzyme is higher than the oxidation activity of the type 1 enzyme
brenda
-
expression and activity of isozyme 11beta-HSD2 in probes of seven different women with ovarian cancer of different types, overview
brenda
-
mainly isozyme 11beta-HSD2, the concentration of isozyme 11beta-HSD1 is 10-100fold lower, expression analysis, isozyme 11beta-HSD2 shows strong expression and activity in quiescent cells
brenda
-
at baseline, mRNA levels are similar in diabetic and control sugjects for 11beta-HSD1, 11beta-HSD2, and hexose-6-phosphate dehydrogenase. 11beta-HSD1 activity is reduced in diabetic subjects, while 11beta-HSD2 activity is increased. After application of dexamethasone, 11beta-HSD1 mRNA increases in both groups, whereas 11beta-HSD2 mRNA decreases. 11beta-HSD1 activity increases in diabetic subjects, but not in controls, whereas 11beta-HSD2 activity does not change in either group; mRNA levels are similar in diabetic and control subjects for 11beta-hydroxysteroid dehydrogenase 1 and 11beta-hydroxysteroid dehydrogenase 2. 11beta-Hydroxysteroid dehydrogenase 2-activity is higher in diabetic patients. After treatment with dexamethasone, 11beta-hydroxysteroid dehydrogenase 1-mRNA increases in both groups, whereas 11beta-hydroxysteroid dehydrogenase 2-mRNA decreases. 11beta-Hydroxysteroid dehydrogenase 1-activity increases in diabetic patients, but not in control, whereas 11beta-hydroxysteroid dehydrogenase 2-activity does not change in either group
brenda
-
isoform 11beta-HSD1 is clearly expressed while isoform 11beta-HSD2 is much less prominent, 11beta-HSD1 protein expression predominates in endothelial cells and varies during periods of growth
brenda
additional information
-
high-fat fed animals overexpress 11beta-hydroxysteroid dehydrogenase type 2 in subcutaneous but not in retroperitoneal fat. Enzyme mRNA levels strongly correlate in both tissues with different parameters related to obesity, such as body weight, adiposity, and insulin resistance
brenda
-
11beta-HSD2 in the adult brain is thought to protect mineralocorticoid receptors from inactivation by corticosterone
brenda
-
11beta-HSD2 in the adult brain is thought to protect mineralocorticoid receptors from inactivation by corticosterone
brenda
11HSD1 is highly expressed in various brain structures, including the hippocampus
brenda
-
pronounced 11beta-hydroxysteroid dehydrogenase activity in presence of NADP+ and NAD+
brenda
-
pronounced 11beta-hydroxysteroid dehydrogenase activity in presence of NADP+ and NAD+
brenda
-
isoform 11beta-HSD1 is clearly expressed while isoform 11beta-HSD2 is much less prominent, 11beta-HSD1 protein expression predominates in endothelial cells and varies during periods of growth
brenda
-
isoform 11beta-HSD1 is clearly expressed while isoform 11beta-HSD2 is much less prominent, 11beta-HSD1 protein expression predominates in endothelial cells and varies during periods of growth
brenda
-
of animals that received betamethasone as a fetus, or whose mothers received betamethasone during pregnancy. Adult animals demonstrate increased mineralocorticoid and 11beta-HSD2 mRNA levels
brenda
-
similar amounts of protein for both isoform 11beta-HSD1 and 11beta-HSD2. 11beta-HSD1 functions as a dehydrogenase with no significant reverse reductase activity and colocalizes with cyclooxygenase COX-2 in proximal tubule cells. No colocalization of COX-2 with isoform 11beta-HSD2 in cortical collecting duct
brenda
-
11betaHSD2 mRNA and protein expression increases significantly after treatment with estradiol; renal 11beta-HSD1 mRNA and protein expression decrease to very low levels after estradiol treatment
brenda
-
hepatic artery, portal vein, and hepatic vein, local cortisol concentrations, overview
brenda
-
adult and fetal lung and cultured fetal lung explant contain similar amounts of isoform HSD2 mRNA. Higher levels of HSD2 protein are detected in fetal lung tissue than in adult lung, with expression being restricted to a subset of epithelial cells in the fetal lung tissue. Differentiated fetal lung explants express higher levels of enzyme protein than undifferentiated explants
brenda
-
constitutes an important barrier for 11-OH steroids during pregnancy between maternal and fetal organism, presence of two isoforms
brenda
-
the 11beta-HSD2 expression and activity is 7-8fold higher compared to 11beta-HSD1 in the chorionic plate of small gestational age placentas
brenda
-
presence of 11beta-hydroxysteroid dehydrogenase mRNA transcripts and protein in all tissues of the reproductive tract examined, but cortison-cortisol interconversion is undetectable in the corpus and cauda epididymides, vas deferens, vesicular and prostate glands
brenda
-
pronounced 11beta-hydroxysteroid dehydrogenase activity in presence of NADP+ and NAD+
brenda
-
presence of 11beta-hydroxysteroid dehydrogenase mRNA transcripts and protein in all tissues of the reproductive tract examined, but cortison-cortisol interconversion is undetectable in the corpus and cauda epididymides, vas deferens, vesicular and prostate glands
brenda
-
presence of 11beta-hydroxysteroid dehydrogenase mRNA transcripts and protein in all tissues of the reproductive tract examined, but cortison-cortisol interconversion is undetectable in the corpus and cauda epididymides, vas deferens, vesicular and prostate glands
brenda
additional information
-
normotensive persons and patients with low renin hypertension, LREH, expression and activity of isozyme 11beta-HSD2
brenda
additional information
-
low expression in liver, ovary, prostate gland, and testis
brenda
additional information
-
isozyme 11beta-HSD1 expression is about 30% reduced in castrated male rats, while expression of isozyme 11beta-HSD2 is increased, overview
brenda
additional information
-
isozyme 11beta-HSD2 expression is highly reduced in proliferating cells
brenda
additional information
-
isozyme 11beta-HSD2activity and plasma corticosterone are determined in toads from pre- (PR), post- (P), and reproductive (R) periods, activity is highest in P period, overview
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
additional information
-
subcellular localization of isozyme 11beta-HSD2, overview, isozyme 11beta-HSD2 activity and plasma corticosterone are determined in toads from pre- (PR), post- (P), and reproductive (R) periods, overview
-
brenda
1beta-hydroxysteroid dehydrogenase 2 activity in suirrel monkey kidney microsomes is 3- to 7-times higher than that seen in microsomes from pig or rabbit. Enzyme protein is 4- to 9-times greater in suirrel monkey kidney microsomes than in microsomes from pig or rabbit
-
brenda